Zhejiang Jingxin Pharmaceutical Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jin Zhiping

Chief executive officer

CN¥1.2m

Total compensation

CEO salary percentage	n/a
CEO tenure	11.1yrs
CEO ownership	n/a
Management average tenure	no data
Board average tenure	5.1yrs

Recent management updates

Recent updates

We Think Zhejiang Jingxin Pharmaceutical (SZSE:002020) Can Stay On Top Of Its Debt

Oct 04

Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) Low P/E No Reason For Excitement

Sep 12

Zhejiang Jingxin Pharmaceutical (SZSE:002020) Has Announced A Dividend Of CN¥0.30

May 21

Zhejiang Jingxin Pharmaceutical's (SZSE:002020) Problems Go Beyond Weak Profit

Apr 08

We Think Zhejiang Jingxin Pharmaceutical (SZSE:002020) Can Stay On Top Of Its Debt

Mar 29

CEO

Jin Zhiping (43 yo)

11.1yrs

Tenure

CN¥1,231,400

Compensation

Mr. Jin Zhiping has been Non-Independent Director of Zhejiang Jingxin Pharmaceutical Co., Ltd. since October 8, 2013 and serves as its President.

Board Members

Name	Position	Tenure	Compensation	Ownership
Jin Zhiping	President & Director	11.1yrs	CN¥1.23m	no data
Chen Meili	VP, CFO & Director	11.1yrs	CN¥957.20k	0.044% CN¥ 4.6m
Yunfei Hong	Secretary of the Board & Non-Independent Director	5.1yrs	CN¥940.20k	no data
Lv Gang	Chairman of the Board	11.1yrs	CN¥1.64m	20.77% CN¥ 2.2b
Wang Nengneng	Vice Chairman	11.1yrs	CN¥1.17m	0.42% CN¥ 43.9m
Tianqing Hu	Chairman of the Supervisory Board	no data	CN¥310.80k	no data
Fen Juan Lin	Employee Representative Member of the Supervisory Board	no data	no data	no data
Pan Xu	Independent Director	2.1yrs	CN¥80.00k	no data
Xiao Jun Xu	Supervisor	5.1yrs	no data	no data
Hu Wan	Non-Independent Director	2.1yrs	CN¥683.40k	no data
Zhang Daliang	Independent Director	2.1yrs	CN¥80.00k	no data
Lei Ying	Independent Director	2.1yrs	CN¥80.00k	no data

5.1yrs

Average Tenure

51yo

Average Age

Experienced Board: 002020's board of directors are considered experienced (5.1 years average tenure).

Zhejiang Jingxin Pharmaceutical Management

Management criteria checks 3/4

Key information

Recent management updates

Zhejiang Jingxin Pharmaceutical Co., Ltd., Annual General Meeting, Apr 22, 2024

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces Directorate Appointments

High number of new directors

Zhejiang Jingxin Pharmaceutical Co., Ltd., Annual General Meeting, Apr 22, 2022

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.18 in 3Q 2023)

We Think Zhejiang Jingxin Pharmaceutical (SZSE:002020) Can Stay On Top Of Its Debt

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Investor sentiment improves as stock rises 21%

Zhejiang Jingxin Pharmaceutical Co., Ltd.'s (SZSE:002020) Low P/E No Reason For Excitement

New minor risk - Earnings quality

Now 21% overvalued

Second quarter 2024 earnings released: EPS: CN¥0.27 (vs CN¥0.19 in 2Q 2023)

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 15, 2024

Zhejiang Jingxin Pharmaceutical (SZSE:002020) Has Announced A Dividend Of CN¥0.30

Dividend of CN¥0.30 announced

Zhejiang Jingxin Pharmaceutical's (SZSE:002020) Problems Go Beyond Weak Profit

Full year 2023 earnings: EPS misses analyst expectations

Zhejiang Jingxin Pharmaceutical Co., Ltd., Annual General Meeting, Apr 22, 2024

We Think Zhejiang Jingxin Pharmaceutical (SZSE:002020) Can Stay On Top Of Its Debt

Investor sentiment deteriorates as stock falls 16%

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.20 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.19 in 2Q 2022)

New minor risk - Shareholder dilution

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 15, 2023

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan, Payable on 24 May 2023

Full year 2022 earnings released: EPS: CN¥0.73 (vs CN¥0.75 in FY 2021)

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.20 in 3Q 2021)

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces Directorate Appointments

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.17 in 2Q 2021)

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces 2021 Final Profit Distribution Plan, Payable on 25 May 2022

Zhejiang Jingxin Pharmaceutical Co., Ltd. Approves 2021 Profit Distribution Plan At the Annual General Meeting Held on April 22, 2022

High number of new directors

Zhejiang Jingxin Pharmaceutical Co., Ltd., Annual General Meeting, Apr 22, 2022

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces the Final Profit Distribution Proposal for 2021

Full year 2021 earnings released: EPS: CN¥0.74 (vs CN¥0.82 in FY 2020)

Investor sentiment improved over the past week

Full year 2021 earnings: EPS misses analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.17 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.15 in 2Q 2020)

Zhejiang Jingxin Pharmaceutical Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2020, Payable on May 28, 2021

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.13 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.98 (vs CN¥0.73 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.98 (vs CN¥0.73 in FY 2019)

Earnings beat expectations, revenue disappoints

New 90-day low: CN¥10.31

New 90-day low: CN¥10.72

New 90-day low: CN¥11.21

Third quarter earnings released

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Earnings released

Zhejiang Jingxin Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥15.10

Zhejiang Jingxin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 499.999996 million in funding from Jingxin Holding Group Co., Ltd.

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age